DMII Q2 2025 Earnings Report — Drugs Made In America Acquisition II Corp. Ordinary Shares Revenue & Financial Results | Market Cap Arena

Drugs Made In America Acquisition II Corp. Ordinary SharesDMII

Q2 2025 Earnings

Reported June 30, 2025

Quarter Comparison

Revenue

Operating Income

EPS (Diluted)

Metric	Q2 2025	Q1 2025	Q2 2024	QoQ Change	YoY Change
Revenue	$0	$0	—	—	—
Op. Income	-$38.1K	-$59.3K	—	35.8%	—
EPS (Diluted)	$0.00	$-0.00	—	100.0%	—

Income Statement

Item	Amount
REVENUE	$0
Cost of Revenue	$0
GROSS PROFIT	$0
R&D Expenses	$0
Selling & Marketing	$0
General & Administrative	$38.1K
SG&A Expenses	$38.1K
Other Expenses	$0
Operating Expenses	$38.1K
Cost & Expenses	$38.1K
OPERATING INCOME	-$38.1K
Interest Income	$0
Interest Expense	$0
Other Income/Expenses	$0
INCOME BEFORE TAX	-$38.1K
Income Tax Expense	$0
Net Income from Continuing Ops	-$38.1K
Net Income from Discontinued Ops	$0
Other Adjustments	$0
NET INCOME	-$38.1K
Net Income Deductions	$0
BOTTOM LINE NET INCOME	-$38.1K
D&A	$0
EBIT	-$38.1K
EBITDA	-$38.1K
EPS	$0
EPS Diluted	$0

Balance Sheet

Item	Amount
Cash & Equivalents	$4.4K
Short-Term Investments	$0
Net Receivables	$2.6K
Inventory	$0
Other Current Assets	$0
TOTAL CURRENT ASSETS	$11.6K
PP&E (Net)	$0
Goodwill	$0
Intangible Assets	$0
Long-Term Investments	$0
Tax Assets	$0
Other Non-Current Assets	$101.8K
TOTAL NON-CURRENT ASSETS	$101.8K
TOTAL ASSETS	$113.4K
Account Payables	$0
Short-Term Debt	$297.3K
Deferred Revenue	$0
Other Current Liabilities	$0
TOTAL CURRENT LIABILITIES	$327.5K
Long-Term Debt	$0
Deferred Revenue NC	$0
Deferred Tax Liabilities	$0
Other Non-Current Liabilities	$0
TOTAL NON-CURRENT LIABILITIES	$0
TOTAL LIABILITIES	$327.5K
Common Stock	$1.4K
Additional Paid-In Capital	$33.6K
Retained Earnings	-$249.1K
Treasury Stock	$0
Accum. Other Comp. Income	$0
Other Equity	$0
TOTAL STOCKHOLDERS' EQUITY	-$214.1K
Minority Interest	$0
TOTAL EQUITY	-$214.1K
TOTAL LIABILITIES & EQUITY	$113.4K
Total Debt	$297.3K
Net Debt	$292.9K